Sedana Medical receives approval for European dossier
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation of mechanically ventilated adult patients during intensive care and should only be administered via the medical device AnaConDa. From October 1[st], AnaConDa will change name to Sedaconda ACD.The application was approved through a decentralized European procedure (DCP) by the German Medicines Agency BfArM (acting as reference country) in